Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Candida auris, a multidrug-resistant yeast that causes invasive infections, was first described in 2009 in Japan and has since been reported from several countries. METHODS: To understand the global emergence and epidemiology of C. auris, we obtained isolates from 54 patients with C. auris infection from Pakistan, India, South Africa, and Venezuela during 2012-2015 and the type specimen from Japan. Patient information was available for 41 of the isolates. We conducted antifungal susceptibility testing and whole-genome sequencing (WGS). RESULTS: Available clinical information revealed that 41% of patients had diabetes mellitus, 51% had undergone recent surgery, 73% had a central venous catheter, and 41% were receiving systemic antifungal therapy when C. auris was isolated. The median time from admission to infection was 19 days (interquartile range, 9-36 days), 61% of patients had bloodstream infection, and 59% died. Using stringent break points, 93% of isolates were resistant to fluconazole, 35% to amphotericin B, and 7% to echinocandins; 41% were resistant to 2 antifungal classes and 4% were resistant to 3 classes. WGS demonstrated that isolates were grouped into unique clades by geographic region. Clades were separated by thousands of single-nucleotide polymorphisms, but within each clade isolates were clonal. Different mutations in ERG11 were associated with azole resistance in each geographic clade. CONCLUSIONS: C. auris is an emerging healthcare-associated pathogen associated with high mortality. Treatment options are limited, due to antifungal resistance. WGS analysis suggests nearly simultaneous, and recent, independent emergence of different clonal populations on 3 continents. Risk factors and transmission mechanisms need to be elucidated to guide control measures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“C. auris, a novel Candida species first identified in 2009, has emerged since 2013 as a cause of nosocomial outbreaks in multiple countries across 5 continents.”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [16]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resistance to all three classes of antifungals is reported most commonly in India in South Asia (3%), whereas this is much less common in other regions of the world.122–124”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [122]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Invasive C. auris infections are associated with high mortality rates, with 60% of hospitalizations due to C. auris infections resulting in death (8).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three such mutations, encoding the amino acid substitutions VF125AL (commonly referred to as F126L), Y132F, and K143R, are frequently reported among fluconazole-resistant clinical isolates, and associations between these mutations and specific genetic clades of C. auris have been observed (2).”
From Mutations in TAC1B : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, up to 96% of C. auris may exhibit resistance to fluconazole, an exceptionally high value compared to 0.5–2% for C. albicans, 4–9% for C. tropicalis, 2–6% for C. parapsilosis, and 11–13% for C. glabrata [16,40,41].”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [16]
Experimental — accuracy not yet measured
29 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0
Tamura, K., Stecher, G., Peterson, D., Filipski, A., & Kumar, S. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst197 · Cited by 47,205
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895 · cited 1×
“SNPs were identified using 2 independent pipelines, as described elsewhere (see also the legend to Supplemental Figure 1) [15, 19].”
MethodEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2×
“auris because we did not have a comparison group of patients with other Candida infections from the same institutions [31].”
BackgroundResultNonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data
Chin, C.-S., Alexander, D. H., Marks, P., Klammer, A. A., Drake, J., Heiner, C., Clum, A., Copeland, A., Huddleston, J., Eichler, E. E., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2474 · Cited by 4,029 · cited 1×
“The reference genome was generated by de novo assembly of PacBio reads from isolate B8441, as described elsewhere [18], and used as a reference for single-nucleotide polymorphism (SNP) calling.”
MethodSatoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381 · cited 8×
“To understand the global emergence and epidemiology of C. auris, we obtained isolates from 54 patients with C. auris infection from Pakistan, India, South Africa, and Venezuela during 2012–2015 and the type specimen from Japan.”
BackgroundInfluentialEvolution of pathogenicity and sexual reproduction in eight Candida genomes
Butler, G., Rasmussen, M. D., Lin, M. F., Santos, M. A. S., Sakthikumar, S., Munro, C. A., Rheinbay, E., Grabherr, M., Forche, A., Reedy, J. L., et al. (2009) · Nature · doi:10.1038/nature08064 · Cited by 1,065 · cited 1×
“5 Mb, similar to that of other Candida species [25].”
BackgroundSelf-citationKathuria, S., Singh, P. K., Sharma, C., Prakash, A., Masih, A., Kumar, A., Meis, J. F., & Chowdhary, A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00367-15 · Cited by 532 · cited 1×
“It phenotypically resembles Candida haemulonii and requires use of molecular methods for identification [9, 10].”
MethodSelf-citationFirst Three Reported Cases of Nosocomial Fungemia Caused by Candida auris
Lee, W. G., Shin, J. H., Uh, Y., Kang, M. G., Kim, S. H., Park, K. H., & Jang, H.-C. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00319-11 · Cited by 523 · cited 2×
“auris [3], establishing that this new species was capable of causing invasive infections.”
BackgroundPerea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470
Incidence, characteristics and outcome of ICU-acquired candidemia in India
Chakrabarti, A., Sood, P., Rudramurthy, S. M., Chen, S., Kaur, H., Capoor, M., Chhina, D., Rao, R., Eshwara, V. K., Xess, I., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-014-3603-2 · Cited by 454 · cited 1×
“auris may become widely established within certain regions, as evidenced by the fact that it now accounts for nearly 5% of candidemia in Indian intensive care units [5].”
Background
Cited by
Items 601–700 of 1,007
Cheng, Y., Roma, J. S., Shen, M., Fernandes, C. M., Tsang, P. S., Forbes, H. J., Boshoff, H. I., Lazzarini, C., Poeta, M. D., Zheng, W., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01305-20 · Cited by 30
“Gene mutations in the ERG11 gene encoding the target of azole antifungal drugs (cytochrome P450 lanosterol 14a-demethylase) are found in the South American (Y132F) and South Asian (Y132F or K143R) clades and are associated with reduced susceptibility to fluconazole (6, 11).”
BackgroundCandida auris Biofilm Colonization on Skin Niche Conditions
Uppuluri, P. (2020) · mSphere · doi:10.1128/msphere.00972-19 · Cited by 30
“Candida auris is an emerging multidrug-resistant fungal pathogen that can cause invasive infections predominantly in immunocompromised hospitalized patients (1, 2).”
BackgroundFuture Research Priorities in Fungal Resistance
McCarthy, M. W., Denning, D. W., & Walsh, T. J. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix103 · Cited by 32
“The emergence of Candida auris may require reconfiguration of the assay, because this pathogen typically displays high levels of resistance to existing antifungal agents [74, 75].”
BackgroundInvasive Candidiasis: Epidemiology and Risk Factors
Cortés, J. A., & Corrales, I. F. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81813 · Cited by 34
Müller, P., Tan, C., Ißleib, U., Paßvogel, L., Eilts, B., & Steinhauer, K. (2020) · Journal of Hospital Infection · doi:10.1016/j.jhin.2020.05.026 · Cited by 30
Broad-spectrum antifungal activities and mechanism of drimane sesquiterpenoids
Edouarzin, E., Horn, C., Paudyal, A., Zhang, C., Lu, J., Tong, Z., Giaever, G. N., Nislow, C., Veerapandian, R., Hua, D. H., et al. (2020) · Microbial Cell · doi:10.15698/mic2020.06.719 · Cited by 30
Molecular Characterization of Candida auris Isolates at a Major Tertiary Care Center in Lebanon
Reslan, L., Araj, G. F., Finianos, M., Asmar, R. G., Hrabák, J., Dbaibo, G. S., & Bitar, I. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.770635 · Cited by 29
Odiba, A. S., Durojaye, O. A., Ezeonu, I. M., Mgbeahuruike, A. C., & Nwanguma, B. C. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s360973 · Cited by 33
Alanio, A., Snell, H. M., Cordier, C., Desnos-Olivier, M., Dellière, S., Aissaoui, N., Sturny-Leclère, A., Da Silva, E., Eblé, C., Rouveau, M., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01833-22 · Cited by 28
Self-citationRaman Metabolomics of Candida auris Clades: Profiling and Barcode Identification
Pezzotti, G., Kobara, M., Nakaya, T., Imamura, H., Fujii, T., Miyamoto, N., Adachi, T., Yamamoto, T., Kanamura, N., Ohgitani, E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911736 · Cited by 30
“Its clinical isolates, which have been categorized into four major distinct geographical clades (referred to as Clade I~IV) [3], exhibit clade- and sub-clade specific”
BackgroundGuo, L., Xiao, M., Cao, B., Qu, F., Zhan, Y., Hu, Y., Wang, X., Liang, G., Gu, H., Qi, J., et al. (2017) · Future Microbiology · doi:10.2217/fmb-2017-0036 · Cited by 30
Breda, G. L., Tuon, F. F., Meis, J. F. G. M., Herkert, P. F., Hagen, F., de Oliveira, L. Z., Dias, V. D. C., da Cunha, C. A., & Queiroz‐Telles, F. (2017) · Medical Mycology · doi:10.1093/mmy/myx077 · Cited by 29
Self-citationCandida auris, what do paediatricians need to know?
Warris, A. (2018) · Archives of Disease in Childhood · doi:10.1136/archdischild-2017-313960 · Cited by 31
Candida auris Bloodstream Infections in Russia
Barantsevich, N. E., Ветохина, А. В., Ayushinova, N. I., Oe, O., & Barantsevich, E. P. (2020) · Antibiotics · doi:10.3390/antibiotics9090557 · Cited by 33
Yi, Q., Xiao, M., Fan, X., Zhang, G., Yang, Y., Zhang, J., Duan, S., Cheng, J., Li, Y., Zhou, M., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.628828 · Cited by 51
“It is associated with high rates of morbidity and mortality in immunocompromised individuals and critically ill patients (Miceli et al., 2011; Lockhart et al., 2017).”
BackgroundBaker, A. D., Gold, J. A. W., Forsberg, K., Jones, S., & Lyman, M. M. (2025) · Emerging Infectious Diseases · doi:10.3201/eid3108.250315 · Cited by 27
Junker, K., Bravo Ruiz, G., Lorenz, A., Walker, L., Gow, N. A. R., & Wendland, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-33199-z · Cited by 27
Jaromin, A., Żarnowski, R., Markowski, A., Zagórska, A., Johnson, C. J., Etezadi, H., Kihara, S., Mota‐Santiago, P., Nett, J. E., Boyd, B. J., et al. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00955-23 · Cited by 28
Almajid, A., Bazroon, A. A., Al-Awami, H., Albarbari, H., Alqahtani, I., Almutairi, R., Alsuwayj, A., Alahmadi, F., Aljawad, J., Alnimer, R., et al. (2024) · Cureus · doi:10.7759/cureus.59210 · Cited by 50
“Nevertheless, MGX continued to inhibit a substantial proportion of these Candida species [20] [21].”
BackgroundCollateral sensitivity counteracts the evolution of antifungal drug resistance in Candida auris
Carolus, H., Sofras, D., Boccarella, G., Jacobs, S., Biriukov, V. V., Goossens, L., Chen, A., Vantyghem, I., Verbeeck, T., Pierson, S., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01811-w · Cited by 31
“Strain B8441 can be considered the type strain for C. auris , as it is the only curated C. auris genome on Candida Genome Database 94 (candidagenome.org) and one of the most commonly used reference strains in research 9,46,56,57,95–100 .”
Silva, L. N., de Mello, T. P., Ramos, L. S., Branquinha, M. H., & dos Santos, A. L. S. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191025152412 · Cited by 29
Alvarado, M. I., Álvarez, J. B., Lockhart, S. R., Valentín, E., Gaitán, A. C. R., Eraso, E., & de Groot, P. W. J. (2020) · Mycoses · doi:10.1111/myc.13204 · Cited by 30
Self-citationCaballero, U., Eraso, E., Quindós, G., & Jauregizar, N. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091333 · Cited by 29
“auris, both intrinsic and acquired resistance are the norm [3,4].”
BackgroundWillaert, R., Kayacan, Y., & Devreese, B. V. (2021) · Pathogens · doi:10.3390/pathogens10111397 · Cited by 27
Emergence of Candida auris in intensive care units in Algeria
Zerrouki, H., Ibrahim, A., Rebiahi, S., Elhabiri, Y., Benhaddouche, D., de Groot, T., Meis, J. F. G. M., Rolain, J., & Bittar, F. (2022) · Mycoses · doi:10.1111/myc.13470 · Cited by 29
Self-citationWright, M. L., Drake, D., Link, D. G., & Berg, J. A. (2023) · Nursing Outlook · doi:10.1016/j.outlook.2023.101919 · Cited by 33
Strategies and opportunities for engineering antifungal peptides for therapeutic applications
Konakbayeva, D., & Karlsson, A. J. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.102926 · Cited by 29
Insights and Perspectives on the Role of Proteostasis and Heat Shock Proteins in Fungal Infections
Neves‐da‐Rocha, J., Santos-Saboya, M. J., Lopes, M. E. R., Rossi, A., & Martinez-Rossi, N. M. (2023) · Microorganisms · doi:10.3390/microorganisms11081878 · Cited by 32
“Candida auris, a multidrug-resistant species, has been identified as a global health issue, with mortality rates of approximately 60% in some countries [2].”
BackgroundWang, Y., & Xu, J. (2024) · Journal of Fungi · doi:10.3390/jof10010086 · Cited by 31
“Indeed, many genes containing SNPs associated with drug susceptibility differences belonged to the “unknown” function category, largely due to the incomplete annotation of the C. auris genome and other Candida genomes [18].”
BackgroundRegulated Cell Death as a Therapeutic Target for Novel Antifungal Peptides and Biologics
Yeaman, M. R., Büttner, S., & Thevissen, K. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/5473817 · Cited by 28
“auris, is among the most significant public health concerns related to fungal infections in recent memory [12].”
BackgroundTits, J., Cools, F., Cremer, K. D., Brucker, K. D., Berman, J. G., Verbruggen, K., Gevaert, B., Cos, P., Cammue, B. P. A., & Thevissen, K. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01296-20 · Cited by 30
“reported to develop resistance to the other classes of antifungals (27, 30).”
BackgroundAnalysis of a Candida auris Outbreak Provides New Insights into an Emerging Pathogen
Wickes, B. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02083-19 · Cited by 27
“However, multidrug resistance has been found to be frequent (8), and panfungal resistance has been described (18).”
BackgroundMethodDu, M., Hu, W., Tamura, T., Alshahni, M. M., Satoh, K., Yamanishi, C., Naito, T., & Makimura, K. (2021) · Mycopathologia · doi:10.1007/s11046-020-00526-w · Cited by 28
Schroeder, J. A., Wilson, C. M., & Pappas, P. G. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.11.007 · Cited by 31
Genomic Characterizations of Clade III Lineage of Candida auris, California, USA
Price, T. K., Mirasol, R., Ward, K. W., Dayo, A. J., Hilt, E. E., Chandrasekaran, S., Garner, O. B., Maurice, A. D. S., & Yang, S. (2021) · Emerging infectious diseases · doi:10.3201/eid2704.204361 · Cited by 26
“auris as an urgent threat to public health (6), highlighting the need for active surveillance and appropriate infection prevention.”
BackgroundGharehbolagh, S. A., Izadi, A., Talebi, M., Sadeghi, F., Zarrinnia, A., Zarei, F., Darmiani, K., Borman, A. M., & Mahmoudi, S. (2021) · Mycoses · doi:10.1111/myc.13277 · Cited by 28
Ennis, C. L., Hernday, A. D., & Nobile, C. J. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01820-21 · Cited by 23
Barião, P. H. G., Tonani, L., Brancini, G. T. P., Nascimento, É., Braga, G. Ú. L., Wainwright, M., & Kress, M. R. V. Z. (2022) · Photochemical & Photobiological Sciences · doi:10.1007/s43630-022-00258-4 · Cited by 27
First Cases of Candida auris in a Referral Intensive Care Unit in Piedmont Region, Italy
Corcione, S., Montrucchio, G. G., Shbaklo, N., Benedetto, I. D., Sales, G., Cedrone, M., Vita, D., Costa, C. S., Zozzoli, S., Zaccaria, T., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10081521 · Cited by 26
Small molecules for combating multidrug-resistant superbug Candida auris infections
Tu, J., Liu, N., Huang, Y., Yang, W., & Sheng, C. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.001 · Cited by 29
“Turbinmicin (40), a highly oxidized polyketide, was identified to possess broad-spectrum inhibitory activity against Candida spp.”
BackgroundRecent Antifungal Pipeline Developments against Candida auris: A Systematic Review
Treviño‐Rangel, R. D. J., González, G. M., Montoya, A. M., Rojas, O. C., Elizondo-Zertuche, M., & Álvarez‐Villalobos, N. A. (2022) · Journal of Fungi · doi:10.3390/jof8111144 · Cited by 29
“Five phylogenetically distinct clades (South Asian, East Asian, South African, South American, and Iranian) have been described based on whole-genome sequencing of clinical isolates from different continents, suggesting a simultaneous emergence [4,5].”
BackgroundRowlands, J. V., Dufort, E. M., Chaturvedi, S., Zhu, Y., Quinn, M., Bucher, C., Erazo, R., Haley, V. B., Kuang, J., Ostrowsky, B. E., et al. (2023) · American Journal of Infection Control · doi:10.1016/j.ajic.2023.01.012 · Cited by 28
Self-citationVito, M. D., Garzoli, S., Rosato, R., Mariotti, M., Gervasoni, J., Santucci, L., Ovidi, E., Cacaci, M., Lombarini, G., Torelli, R., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04385-22 · Cited by 32
Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations
Flanagan, S., Walker, H., Ong, V. S., & Sandison, T. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01339-23 · Cited by 28
Borriello, F., Zanoni, I., & Granucci, F. (2020) · European Journal of Immunology · doi:10.1002/eji.201848054 · Cited by 28
Recent advances and future perspectives in the pharmacological treatment ofCandida aurisinfections
Giacobbe, D. R., Magnasco, L., Sepulcri, C., Mikulska, M., Koehler, P. A., Cornely, O. A., & Bassetti, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1949285 · Cited by 26
Parallel expansion and divergence of an adhesin family in pathogenic yeasts
Smoak, R. A., Snyder, L. F., Fassler, J. S., & He, B. Z. (2023) · GENETICS · doi:10.1093/genetics/iyad024 · Cited by 25
Candida auris: A Systematic Review of a Globally Emerging Fungal Pathogen in Africa
Osaigbovo, I. I., Ekeng, B. E., Davies, A. A., Ebeigbe, E., Bongomin, F., Kanyua, A., Revathi, G., & Oladele, R. O. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad681 · Cited by 30
Selisana, S. M. G., Chen, X., Mahfudhoh, E., Bowolaksono, A., Rozaliyani, A., Orihara, K., & Kajiwara, S. (2024) · Medical Microbiology and Immunology · doi:10.1007/s00430-024-00795-y · Cited by 27
Novel Antifungal Activity of Q-Griffithsin, a Broad-Spectrum Antiviral Lectin
Nabeta, H. W., Kouokam, J. C., Lasnik, A. B., Fuqua, J. L., & Palmer, K. E. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00957-21 · Cited by 28
Stevanović, N. L., Kljun, J., Aleksić, I., Bogojević, S. Š., Milivojević, D., Veselinović, A. M., Turel, I., Djuran, M. I., Nikodinović‐Runić, J., & Glišić, B. Đ. (2022) · Dalton Transactions · doi:10.1039/d2dt00411a · Cited by 28
Katsiari, M., Mavroidi, A., Kesesidis, N., Palla, E., Zourla, K., Ntorlis, K., Konstantinidis, K., Laskou, M., Konstantinos, S., Sakkalis, A., et al. (2023) · Journal of Fungi · doi:10.3390/jof9020243 · Cited by 25
“auris, whole Genome Sequence (WGS) analysis has revealed nearly simultaneous, recent and independent emergence of different clonal populations on three continents [39,40].”
BackgroundTreatment of invasive candidiasis in the era of Candida resistance
Paiva, J.-A., & Pereira, J. M. (2023) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001077 · Cited by 35
Thomsen, J., Abdulrazzaq, N. M., Oulhaj, A., Nyasulu, P. S., Alatoom, A. A., Denning, D. W., Dhaheri, F. A. A., Menezes, G. A., Moubareck, C. A., Senok, A. C., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1244358 · Cited by 30
Epidemiología de las micosis invasoras: un paisaje en continuo cambio
Quindós, G. (2018) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2018.07.002 · Cited by 28
Biswas, C., Wang, Q., van Hal, S. J., Eyre, D. W., Hudson, B. J., Halliday, C. L., Mazsewska, K., Gordon, A. K., Lee, A. S., Irinyi, L., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa158 · Cited by 29
“4 • ofid • BRIEF REPORT notion these are clade I–specific markers of resistance [1, 17].”
BackgroundInfluentialSelf-citationInsights into the Multi-Azole Resistance Profile in Candida haemulonii Species Complex
Silva, L. N., Ramos, L. S., de Oliveira, S. S. C., Magalhães, L. B., Squizani, E. D., Kmetzsch, L., Vainstein, M. H., Branquinha, M. H., & dos Santos, A. L. S. (2020) · Journal of Fungi · doi:10.3390/jof6040215 · Cited by 27
Narayanan, A., Vadnala, R. N., Ganguly, P., Selvakumar, P., Rudramurthy, S. M., Prasad, R., Chakrabarti, A., Siddharthan, R., & Sanyal, K. (2021) · mBio · doi:10.1128/mbio.00905-21 · Cited by 28
“C. auris emerged and evolved simultaneously as distinct geographical clades—South Asian (clade 1), East Asian (clade 2), South African (clade 3), South American (clade 4), and a potential fifth clade from Iran (13, 14).”
BackgroundInfluentialEpidemiology of Cryptococcus gattii, British Columbia, Canada, 1999–2007
Galanis, E. (2010) · Emerging infectious diseases · doi:10.3201/eid1601.090900 · Cited by 33
Nanotechnology-Based Strategies to Combat Multidrug-Resistant Candida auris Infections
Hetta, H. F., Ramadan, Y. N., Al-Kadmy, I. M. S., Ellah, N. H. A., Shbibe, L., & Battah, B. (2023) · Pathogens · doi:10.3390/pathogens12081033 · Cited by 24
“auris has spread around the world as an MDR fungal infection that significantly increases patient death [27,28].”
Rapid in vitro evolution of flucytosine resistance in Candida auris
Phan-Canh, T., Nguyen-Le, D.-M., Luu, P., Khunweeraphong, N., & Kuchler, K. (2025) · mSphere · doi:10.1128/msphere.00977-24 · Cited by 30
Lemons, A. R., McClelland, T. L., Martin, S. B., Lindsley, W. G., & Green, B. J. (2020) · Journal of Hospital Infection · doi:10.1016/j.jhin.2020.04.011 · Cited by 26
“or more commonly administered antifungal drugs [4].”
BackgroundInfluentialPrevalence of Candida auris in Canadian acute care hospitals among at-risk patients, 2018
Garcia-Jeldes, H. F., Mitchell, R., McGeer, A., Rudnick, W., Amaratunga, K., Vallabhaneni, S., Lockhart, S. R., CNISP C. auris Interest Group, Al‐Rawahi, G. N., Brodkin, E., et al. (2020) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-020-00752-3 · Cited by 25
“auris has very rarely caused human infection in the past [1].”
BackgroundSelf-citationGudipati, S., Zervos, M., & Herc, E. S. (2020) · Antibiotics · doi:10.3390/antibiotics9090599 · Cited by 25
“A well-known infection that is hypothesized to have arisen from climate change is Candida auris, which previously existed as a plant saprophyte and gained thermotolerance and salinity tolerance from the effects of climate change on the wetland ecosystem [31,32].”
BackgroundCOVID-19-Associated Fungal Infections: An Urgent Need for Alternative Therapeutic Approach?
Domán, M., & Bànyai, K. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.919501 · Cited by 28
Taori, S. K., Rhodes, J. L., Khonyongwa, K., Szendrôi, A., Smith, M. H., Borman, A. M., Kumarage, J., Brown, C. S., Moore, G., & Desai, N. (2022) · Journal of Hospital Infection · doi:10.1016/j.jhin.2022.06.009 · Cited by 25
Caspofungin Affects Extracellular Vesicle Production and Cargo in Candida auris
Amatuzzi, R. F., Zamith‐Miranda, D., da Rocha, I. F. M., Lucena, A. C. R., Martins, S. D. T., Streit, R. S. A., Staats, C. C., Trentin, G., Almeida, F. B. D. R., Rodrigues, M. L., et al. (2022) · Journal of Fungi · doi:10.3390/jof8100990 · Cited by 25
Ashkenazi‐Hoffnung, L., & Danziger, C. R. (2023) · Journal of Fungi · doi:10.3390/jof9020176 · Cited by 29
“One study aimed at delineating the impact of ERG11 mutations (F125L, Y132F and K143R) on fluconazole susceptibility in C. auris clinical isolates with a Cas9-mediated transformation system [120].”
BackgroundInfluentialGorzalski, A. J., Ambrosio, F. J., Massic, L., Scribner, M. R., Siao, D. D., Hua, C. N., Dykema, P., Schneider, E., Njoku, C., Libuit, K. G., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1198189 · Cited by 24
“C. auris clades were initially identified by geographical region—Clade 1 (South Asian), Clade 2 (East Asian), Clade 3 (African), Clade 4 (South American) and Clade 5 (Middle Eastern) (2, 5).”
BackgroundThe Impact of Climate Change on Human Fungal Pathogen Distribution and Disease Incidence
Hamm, P. S., & Torres-Cruz, T. J. (2024) · Current Clinical Microbiology Reports · doi:10.1007/s40588-024-00224-x · Cited by 28
“Candida auris is resistant to fluconazole and has variable susceptibility to other azoles, amphotericin B, and echino-candins [45].”
InfluentialMulticenter Candida auris outbreak caused by azole‐susceptible clade IV in Pernambuco, Brazil
Spruijtenburg, B., de Almeida, J. N., Ribeiro, F. D. C., Kemmerich, K. K., Baêta, K. F., Meijer, E. F. J., de Groot, T., Meis, J. F. G. M., Colombo, A. L., & Brazilian Candida auris collaborative network (2024) · Mycoses · doi:10.1111/myc.13752 · Cited by 24
Self-citationRamos, L. S., Barbosa, P. F., Lorentino, C. M. A., Lima, J. C., Braga, A. L., Lima, R., Giovanini, L., Casemiro, A. L., Siqueira, N. L. M., da Costa, S. C., et al. (2025) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2025.100354 · Cited by 33
“…et al., 2015; Calvo et al., 2016; Vallabhaneni et al., 2016; Arendrup et al., 2017; Ben-Ami et al., 2017; Fakhim et al., 2017; Larkin et al., 2017; Lockhart et al., 2017; Rudramurthy et al., 2017; Ruiz Gait ´ an et al., 2017; Berkow and Lockhart, 2018; Chowdhary et al., 2018; Hashemi et al.,…”
Ceballos-Garzón, A., Amado, D., Vélez, N., Jiménez-A, M. J., Rodríguez, C., & Parra‐Giraldo, C. M. (2020) · Journal of Fungi · doi:10.3390/jof6020072 · Cited by 26
Echinocandins as Biotechnological Tools for Treating Candida auris Infections
Cândido, E. D. S., Affonseca, F., Cardoso, M. H. E. S., & Franco, O. L. (2020) · Journal of Fungi · doi:10.3390/jof6030185 · Cited by 27
Grand Challenges in Infectious Diseases: Are We Prepared for Worst-Case Scenarios?
Cloeckaert, A., & Kuchler, K. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.613383 · Cited by 24
Identification of disulfiram as a potential antifungal drug by screening small molecular libraries
Hao, W., Qiao, D., Han, Y., Du, N., Li, X., Fan, Y., Ge, X., & Zhang, H. (2020) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2020.12.012 · Cited by 24
Demin, K. A., Refeld, A. G., Bogdanova, A. A., Prazdnova, E. V., Popov, I. V., Kutsevalova, O. Y., Ermakov, A. M., Bren, A. B., Rudoy, D. V., Chistyakov, V. A., et al. (2021) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-021-09776-6 · Cited by 25
Candida auris : An emerging multidrug-resistant pathogen of global significance
Khan, Z., & Ahmad, S. (2017) · Current Medicine Research and Practice · doi:10.1016/j.cmrp.2017.11.004 · Cited by 27
Managing Candida auris fungemias: the results of a prospective and international study
Erdem, H., Şakir-Yildirim, S., Ankaralı, H. Ç., Batırel, A. A., Kul, G., Fidan, G., El‐Kholy, A., Pekok, A. U., Taher, O. M. E. A., Bozkurt, F., et al. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00358-25 · Cited by 23
“multidrug-resistant strains (9).”
InfluentialWhite-Brown switching controls phenotypic plasticity and virulence of Candida auris
Phan-Canh, T., Jenull, S., Bitencourt, T. A., Seiser, S., Moser, D., Motamedi, M., Chowdhary, A., Elbe‐Bürger, A., & Kuchler, K. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115976 · Cited by 24
Self-citationUpdate in Infectious Diseases 2018.
Candel, F. J., Emilov, T., de la Torre, I. D., Ruedas, A., Viñuela-Prieto, J. M., Visiedo, C., Martínez-Jordán, J., López-González, L., Matesanz, M., & Arribi, A. (2018) · PubMed Central · Cited by 25
Hernando-Ortiz, A., Eraso, E., Jauregizar, N., de Groot, P. W. J., Quindós, G., & Mateo, E. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02086-23 · Cited by 25
Candidemia in the cancer patient: diagnosis, treatment, and future directions
McCarthy, M. W., & Walsh, T. J. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2018.1536546 · Cited by 24
Incursions of Candida auris into Australia, 2018
Lane, C. R., Seemann, T., Worth, L. J., Easton, M., Pitchers, W., Wong, J., Cameron, D., Azzato, F., Bartolo, R., Mateevici, C., et al. (2020) · Emerging infectious diseases · doi:10.3201/eid2606.190936 · Cited by 23
“auris with phylogeographic variation have been identified (3).”
BackgroundGuo, L., Yu, S.-Y., Xiao, M., Yang, C.-X., Bao, C., Yu, Y., Ye, L., Yang, Y., Zhang, G., Liu, J., et al. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s255843 · Cited by 25
Agnew‐Francis, K. A., Tang, Y., Lin, X., Low, Y. S., Wun, S. J., Kuo, A., Elias, S. M. A. S. I., Lonhienne, T. G. A., Condon, N. D., Pimentel, B. N. A. D. S., et al. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00229 · Cited by 25
Tetz, G. V., Collins, M. S., Vikina, D., & Tetz, V. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01975-18 · Cited by 24
“78 glabrata, with over 41% isolates reportedly resistant to at least two antifungal classes (18).”
BackgroundVu, C. A., Jimenez, A., Anjan, S., & Abbo, L. M. (2022) · Transplant Infectious Disease · doi:10.1111/tid.13919 · Cited by 23
Four genomic clades of Candida auris identified in Canada, 2012–2019
De Luca, D. G., Alexander, D. C., Dingle, T. C., Dufresne, P. J., Hoang, L. M., Kus, J. V., Schwartz, I. S., Mulvey, M. R., & Bharat, A. (2022) · Medical Mycology · doi:10.1093/mmy/myab079 · Cited by 22
Shivarathri, R., Chauhan, M., Datta, A., Das, D., Karuli, A., Aptekmann, A., Jenull, S., Kuchler, K., Thangamani, S., Chowdhary, A., et al. (2024) · mBio · doi:10.1128/mbio.02748-24 · Cited by 22
Self-citationVirulence Traits and Azole Resistance in Korean Candida auris Isolates
Byun, S. A., Kwon, Y. J., Lee, G. Y., Choi, M. J., Jeong, S. H., Kim, D., Choi, M. H., Kee, S., Kim, S. H., Shin, M., et al. (2023) · Journal of Fungi · doi:10.3390/jof9100979 · Cited by 26
“Hotspot mutations in the drug target gene ERG11 have been identified as the primary mechanism for fluconazole resistance in C. auris , with some clade specificity [6,8].”
InfluentialArendrup, M. C., Lockhart, S. R., & Wiederhold, N. P. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.10.010 · Cited by 22
“Since then, Lockhart et al. [4] reported 35% resistance among 54 isolates from Pakistan, India, South Africa, and Venezuela during 2012–2015, Helleberg et al. reported 0% resistance among 122 isolates from India [5], Ben Abid et al. [6] reported 0% resistance among 122 isolates from India, they…”
Self-citationWilliams, C. C., Gregory, J., & Usher, J. (2024) · Microbiology · doi:10.1099/mic.0.001512 · Cited by 26
Climate change and antimicrobial resistance
Kalanxhi, E., & Laxminarayan, R. (2026) · Nature Reviews Microbiology · doi:10.1038/s41579-026-01285-z · Cited by 32
“C. auris was first identified in 2009 in Japan, but by 2015, drug-resistant strains belonging to unique clades with significant genetic diversity were detected on three continents 144 .”
Anticapsular and Antifungal Activity of α-Cyperone
Horn, C., & Vediyappan, G. (2021) · Antibiotics · doi:10.3390/antibiotics10010051 · Cited by 25
“auris, is a major concern due to its pan-antifungal resistance, persistence in hospital environments as well as its invasive virulence potential with a high mortality rate (60%) [5,6].”
BackgroundLee, H., Choi, S. H., Oh, J., Koo, J., Lee, H. J., Cho, S., Shin, J. H., Lee, H. K., Kim, S., Lee, C. H., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01253-21 · Cited by 27
Draft Genome Sequences of 19 Clinical Isolates of Candida auris from Hong Kong
Tse, H., Tsang, A. K. L., Chu, Y.-W., & Tsang, D. N. C. (2021) · Microbiology Resource Announcements · doi:10.1128/mra.00308-20 · Cited by 25
“SRR3883465 [clade IV/South America]), were added to the analysis (9).”
BackgroundHoo, L. S. (2017) · Journal of Liposome Research · doi:10.1080/08982104.2017.1360345 · Cited by 22
Hao, W., Wang, Y., Xi, Y., Yang, Z., Zhang, H., & Ge, X. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.09.018 · Cited by 21
Bravo-Chaucanés, C. P., Vargas‐Casanova, Y., Chitiva, L. C., Ceballos-Garzón, A., Costa, G. M., & Parra‐Giraldo, C. M. (2022) · Journal of Fungi · doi:10.3390/jof8080784 · Cited by 25
Metadata
- Authors
- Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., Berkow, E. L., Castanheira, M., Magobo, R. E., Jabeen, K., Asghar, R. J., Meis, J. F., Jackson, B., Chiller, T., & Litvintseva, A. P.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Aga Khan University (PK)
- University of Delhi (IN)
- National Health Laboratory Service (ZA)
- Universidade Federal de São Paulo (BR)
- Universidad del Zulia (VE)
- Broad Institute (US)
- JMI Laboratories (US)
- Radboud University Nijmegen (NL)
- ORCID
- Lockhart, Shawn R.
- Vallabhaneni, Snigdha
- Farooqi, Joveria
- Chowdhary, Anuradha
- Govender, Nelesh P.
- Colombo, Arnaldo Lopes
- Cuomo, Christina A.
- Desjardins, Christopher A.
- Berkow, Elizabeth L.
- Castanheira, Mariana
- Magobo, Rindidzani E.
- Jabeen, Kauser
- Asghar, Rana J.
- Meis, Jacques F.
- Jackson, Brendan
- Chiller, Tom
- Litvintseva, Anastasia P.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-10-20
- Volume
- 64
- Issue
- 2
- Pages
- 134-140
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC5215215
- OpenAlex
- W2536287248
- Semantic Scholar
- c8d8e54651d8fb7a7ece68270cd2630d1cd0df39
- Cited by
- 1,662
- References
- 32
- Citations by year
- 2026: 196 · 2025: 194 · 2024: 203 · 2023: 186 · 2022: 160 · 2021: 178 · 2020: 187 · 2019: 152 · 2018: 116 · 2017: 81 · 2016: 5
- FWCI
- 108.27
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- public-domain
- Locations
- Clinical Infectious Diseases (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (U19AI110818)
- United States Agency for International Development (4-338/PAK-US/HEC/2010/932)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- Candida auris, multidrug resistance, antifungal resistance, clonal populations, ERG11 mutations, azole resistance, fluconazole resistance, bloodstream infection, invasive candidiasis, nosocomial infections, risk factors, transmission, whole genome sequencing, antifungal susceptibility
- MeSH terms
- Whole Genome Sequencing, Adolescent, Adult, Aged, Antifungal Agents, Candida, Candidiasis, Child, Child, Preschool, Cytochrome P-450 Enzyme System, Female, Humans, Infant, Infant, Newborn, Male, Microbial Sensitivity Tests, Middle Aged, Mutation, Phylogeny, RNA, Ribosomal, 28S, Global Health, Genome, Fungal, Drug Resistance, Multiple, Polymorphism, Single Nucleotide, DNA, Ribosomal Spacer, Drug Resistance, Fungal, Young Adult, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.